Related Experiment Video
Updated: Feb 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Identification of Novel Target for Osteosarcoma by Network Analysis
Li-Qiang Zhi1, Yi-Xin Yang2, Shu-Xin Yao1
1Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Abstract:
BACKGROUND Osteosarcoma (OS) is a highly complicated bone cancer involving imbalance of signaling transduction networks in cells. Development of new anti-osteosarcoma drugs is very challenging, mainly due to lack of known key targets. MATERIAL AND METHODS In this study, we attempted to reveal more promising targets for drug design by "Target-Pathway" network analysis, providing the new therapeutic strategy of osteosarcoma. The potential targets used for the treatment of OS were selected from 4 different sources: DrugBank, TCRD database, dbDEMC database, and recent scientific literature papers. Cytoscape was used for the establishment of the "Target-Pathway" network. RESULTS The obtained results suggest that tankyrase 2 (TNKS2) might be a very good potential protein target for the treatment of osteosarcoma. An in vitro MTT assay proved that it is an available option against OS by targeting the TNKS2 protein. Subsequently, cell cycle and apoptosis assay by flow cytometry showed the TNKS2 inhibitor can obviously induce cell cycle arrest, apoptosis, and mitotic cell death. CONCLUSIONS Tankyrase 2 (TNKS2), a member of the multifunctional poly(ADP-ribose) polymerases (PARPs), could be a very useful protein target for the treatment of osteosarcoma.
Insights
Researchers identified tankyrase 2 (TNKS2) as a promising drug target for osteosarcoma. Targeting TNKS2 effectively inhibits cancer cell growth, induces apoptosis, and causes mitotic cell death in osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma (OS) is a complex bone cancer characterized by dysregulated cellular signaling.
- Developing effective anti-osteosarcoma drugs is hindered by a lack of identified therapeutic targets.
Purpose of the Study:
- To identify novel therapeutic targets for osteosarcoma drug development.
- To establish a "Target-Pathway" network for strategic drug design against OS.
Main Methods:
- Utilized data from DrugBank, TCRD, dbDEMC, and literature to identify potential targets.
- Constructed a "Target-Pathway" network using Cytoscape.
- Validated potential targets through in vitro MTT assays, cell cycle, and apoptosis analyses.
Main Results:
- Tankyrase 2 (TNKS2) emerged as a highly promising protein target for osteosarcoma treatment.
- In vitro assays confirmed TNKS2 targeting as an effective strategy against OS.
- TNKS2 inhibition led to significant cell cycle arrest, apoptosis, and mitotic cell death.
Conclusions:
- Tankyrase 2 (TNKS2), a poly(ADP-ribose) polymerase (PARP) family member, represents a viable therapeutic target for osteosarcoma.
- Targeting TNKS2 offers a new therapeutic strategy for osteosarcoma treatment.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein Networks
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Network Function of a Circuit
Methods of Classification and Identification
Sequence Networks of Rotating Machines
Zero-sequence current induces a voltage drop across the generator's neutral impedance and other...

